Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Risk of events according to OAC in AF and CKD patients

From: Non-vitamin K antagonist oral anticoagulants vs. vitamin-K antagonists in patients with atrial fibrillation and chronic kidney disease: a nationwide cohort study

  Number of events Hazard ratio (95%CI) Standardized absolute risk (95%CI)
Stroke/thromboembolism
 VKA 21 1.00 (reference) 2.4% (1.4–3.5%)
 NOAC 11 0.83 (0.39–1.78) 2.0% (0.8–3.3%)
Major bleeding
 VKA 55 1.00 (reference) 5.9% (4.4–7.5%)
 NOAC 15 0.47 (0.26–0.84) 2.8% (1.5–4.3%)
Myocardial infarction
 VKA 22 1.00 (reference) 2.5% (1.5–3.7%)
 NOAC 7 0.45 (0.18–1.11) 1.1% (0.4–2.2%)
All-cause mortality
 VKA 183 1.00 (reference) 23.3% (20.2–26.3%)
 NOAC 106 0.99 (0.77–1.26) 23.2% (19.4–27.0%)
  1. Abbreviations: CI Confidence interval, OAC Oral anticoagulation, VKA Vitamin-K antagonist, NOAC Nonvitamin K oral anticoagulant